ASRGL1 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the ASRGL1 gene is disrupted in the A-549 human lung adenocarcinoma line. This model provides a robust tool for loss-of-function studies of ASRGL1-dependent metabolic and signaling processes.
The A-549 host cell line originates from a lung carcinoma of a 58-year-old male and serves as an established in vitro model of alveolar Type II pneumocytes. Exhibiting epithelial morphology and adherent growth, these cells are broadly used in lung cancer biology, toxicology, and metabolic research. Their well-characterized signaling milieu, including active mTOR pathway components, makes them particularly suitable for exploring amino acid sensing and stress responses.
ASRGL1 is a bifunctional enzyme with L-asparaginase and beta-aspartyl peptidase activities, hydrolyzing L-asparagine and clearing isoaspartyl peptides. Transcription of ASRGL1 is upregulated by ATF4 during amino acid deprivation, linking it to the GCN2-eIF2??-ATF4 stress axis. ASRGL1 functions as a self-dimer and modulates intracellular asparagine levels, a critical determinant of protein synthesis and cell growth. Its catalytic activity impinges on mTORC1 signaling by affecting downstream phosphorylation of S6K and 4E-BP1, thereby coordinating nutrient availability with growth and autophagy. ASRGL1 also collaborates with ASNS to maintain asparagine homeostasis.
In A-549 adenocarcinoma cells, ASRGL1 knockout disrupts endogenous asparagine metabolism, creating a relevant model to study metabolic dependencies in solid tumors. Lung cancer cells can exhibit reliance on asparagine for proliferation and survival; loss of L-asparaginase activity may sensitize cells to nutrient stress and alter mTORC1 transduction. This polyclonal knockout population enables dissection of adaptive responses, autophagic modulation, and potential synthetic lethal interactions that arise from asparagine deprivation in an epithelial cancer context.
Key research applications include cancer metabolic vulnerability profiling, tumor suppressor analysis, and mechanistic dissection of asparagine-regulated pathways. Researchers can employ this model in proliferation and apoptosis assays, Western blotting for mTOR effectors (e.g., phospho-S6K, 4E-BP1), RT-qPCR, and metabolite quantification. Rescue experiments and pharmacological perturbations may further validate phenotypes. For technical inquiries and custom requests, please contact Ascent Research.
